Surveillance surveys for reemergent trachoma in formerly endemic districts in Nepal From 2 to 10 years after mass drug administration cessation

This study analyzes whether the World Health Organization recommendation for surveillance surveys to be done 2 years after cessation of mass drug administration in districts formerly endemic for trachoma is sufficient to detect reemergence of disease

Comparison of platforms for testing antibody responses against the chlamydia trachomatis antigen Pgp3

This study  reports the sensitivity of MBA and ELISA using a set of specimens from individuals with ocular swab specimens positive by nucleic acid amplification tests (NAATs) and specificity of the MBA, ELISA, and LFA against a panel of pediatric specimens from nonendemic countries and evaluate the characteristics of the ELISA assay using different cutoffs and plate preparation approaches. 

Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial

The WHO recommends 3–5 years of annual mass azithromycin distribution with at least 80% treatment coverage to districts with active trachoma prevalence over 10% among children. This article assesses the efficacy of expanding the coverage target to at least 90% for trachoma control in a mesoendemic region of Niger.

Immunofibrogenic Gene Expression Patterns in Tanzanian Children with Ocular Chlamydia trachomatis Infection, Active Trachoma and Scarring: Baseline Results of a 4-Year Longitudinal Study

The study was conducted in three adjacent trachoma endemic villages in Kilimanjaro and Arusha regions, Northern Tanzania.

Subscribe to RSS - English